147 related articles for article (PubMed ID: 37193156)
1. Efficacy and safety of glucagon-like peptide-1 receptor agonist combined with sodium-glucose co-transporter-2 inhibitor in the treatment of type 2 diabetes mellitus patients with obesity: a retrospective analysis study.
Wang J; Chen Y; Lu Y; Wang H; Zhao Y
Am J Transl Res; 2023; 15(4):2949-2956. PubMed ID: 37193156
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.
Pereira MJ; Lundkvist P; Kamble PG; Lau J; Martins JG; Sjöström CD; Schnecke V; Walentinsson A; Johnsson E; Eriksson JW
Diabetes Ther; 2018 Aug; 9(4):1511-1532. PubMed ID: 29949016
[TBL] [Abstract][Full Text] [Related]
3. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
4. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial.
Harreiter J; Just I; Leutner M; Bastian M; Brath H; Schelkshorn C; Klepochova R; Krššák M; Kautzky-Willer A
Diabetes Obes Metab; 2021 May; 23(5):1129-1139. PubMed ID: 33464703
[TBL] [Abstract][Full Text] [Related]
5. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.
Roth CL; Perez FA; Whitlock KB; Elfers C; Yanovski JA; Shoemaker AH; Abuzzahab MJ
Diabetes Obes Metab; 2021 Feb; 23(2):363-373. PubMed ID: 33026160
[TBL] [Abstract][Full Text] [Related]
6. Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
Ferrannini E; Baldi S; Frías JP; Guja C; Hardy E; Repetto E; Jabbour SA; DeFronzo RA
Diabetes Obes Metab; 2020 Jan; 22(1):99-106. PubMed ID: 31469220
[TBL] [Abstract][Full Text] [Related]
7. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Elkind-Hirsch KE; Chappell N; Seidemann E; Storment J; Bellanger D
J Clin Endocrinol Metab; 2021 Sep; 106(10):3019-3033. PubMed ID: 34097062
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
Gorgojo-Martínez JJ; Serrano-Moreno C; Sanz-Velasco A; Feo-Ortega G; Almodóvar-Ruiz F
Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):129-137. PubMed ID: 28077257
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Wang J; Jin X; An P; Yu S; Mu Y
J Diabetes Res; 2019; 2019():8083417. PubMed ID: 31772945
[TBL] [Abstract][Full Text] [Related]
10. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
12. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
Ridge T; Moretto T; MacConell L; Pencek R; Han J; Schulteis C; Porter L
Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
[TBL] [Abstract][Full Text] [Related]
13. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
van Ruiten CC; Smits MM; Kok MD; Serné EH; van Raalte DH; Kramer MHH; Nieuwdorp M; IJzerman RG
Cardiovasc Diabetol; 2022 Apr; 21(1):63. PubMed ID: 35484607
[TBL] [Abstract][Full Text] [Related]
16. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
[TBL] [Abstract][Full Text] [Related]
17. A
Brown E; Wilton MM; Sprung VS; Harrold JA; Halford JCG; Stancak A; Burgess M; Howarth E; Umpleby AM; Kemp GJ; Wilding JP; Cuthbertson DJ
BMJ Open; 2021 Jul; 11(7):e045663. PubMed ID: 34285005
[TBL] [Abstract][Full Text] [Related]
18. Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus.
Jiang A; Feng Z; Yuan L; Zhang Y; Li Q; She Y
Diabetol Metab Syndr; 2021 Mar; 13(1):34. PubMed ID: 33766125
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.
Wang Y; Xu B; Zhu L; Lou K; Chen Y; Zhao X; Wang Q; Xu L; Guo X; Ji L; Cui Y; Fang Y
Clin Drug Investig; 2017 Dec; 37(12):1107-1115. PubMed ID: 28932995
[TBL] [Abstract][Full Text] [Related]
20. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y; Bajaj M; Yang HC; Ye Y
Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]